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1. Introduction 
Traumatic brain injury (TBI) is a major source of death and severe disability worldwide. In 
the USA alone, this type of injury causes 290,000 hospital admissions, 51,000 deaths, and 
80,000 permanently disabled survivors [1,2]. Intracranial hypertension develops commonly 
in acute brain injury related to trauma [3,4]. Raised Intracranial pressure (ICP) is an 
important predictor of mortality in patients with severe TBI, and aggressive treatment of 
elevated ICP has been shown to reduce mortality and improve outcome [4-11]. Guidelines 
for the Management of Severe TBI, published in the Journal of Neurotrauma in 2007 [12] 
make a Level II recommendation that ICP should be monitored in all salvageable patients 
with a severe TBI (Glasgow Coma Scale [GCS] score of 3–8 after resuscitation) and an 
abnormal computed tomography (CT) scan. ICP monitoring is also recommended in 
patients with severe TBI and a normal CT scan if two or more of the following features are 
noted at admission: age over 40 years, unilateral or bilateral motor posturing, or systolic 
blood pressure < 90 mm Hg (Level III recommendation). Furthermore, ICP should be 
maintained less than 20 mmHg and cerebral perfusion pressure (CPP) between 50 and 70 
mmHg (Level III). 
As in ischemia –reperfusion injuries, the acute post-injury period in TBI is characterized by 
several pathophysiologic processes that start in the minutes to hours following injury and 
may last for hours to days. These result in further neuronal injury and are termed the 
secondary injury. Cellular mechanisms of secondary injury include all of the following: 
apoptosis, mitochondrial dysfunction, excitotoxicity, disruption in ATP metabolism, 
disruption in calcium homeostasis, increase in inflammatory mediators and cells, free 
radical formation, DNA damage, blood-brain barrier disruption, brain glucose utilization 
disruption, microcirculatory dysfunction and microvascular thrombosis [13-50]. All of these 
processes are temperature dependent; they are all aggravated by fever and inhibited by 
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hypothermia [13-50]. In addition, several studies have shown that development of fever 
following TBI is closely linked to intracranial hypertension and worsened outcome [51-53].  
Clinical trials of hypothermia and temperature management for severe traumatic brain 
injury are divided into trials in which hypothermia is used to treat elevated intracranial 
pressure and those in which hypothermia is intended as a neuroprotectant, irrespective of 
intracranial pressure. In this article, we will review the current clinical evidence behind 
therapeutic hypothermia for the treatment of intracranial hypertension (ICH) in severe TBI 
patients, as well as therapeutic hypothermia as a neuroprotectant in severe TBI.  
2. Methods 
We queried the Medline database with the MeSH terms “Hypothermia, induced,” “Fever”, 
“Intracranial Hypertension”, and “Traumatic Brain Injury” from 1993 till 2011. We utilized 
both PubMed and OVID to maximize database penetration. We searched the Cochrane 
Database of Systematic Reviews. We also hand searched bibliographies of relevant citations 
and reviews. Inclusion criteria were double-blind, placebo-controlled, randomized 
controlled trials (RCTs), observational studies or meta-analysesof therapeutic 
hypothermia for TBI patients in which ICPs are monitored.We limited the search to human 
literature; We did not limit language, but we extracted studies that involved only adult 
subjects excluding studies on the pediatric population. Information extracted included 
number of patients, ICP, length of cooling, length of re-warming, outcome, complications, 
methods used to control ICP and the quality of each study. We reviewed the literature 
pertaining to pathophysiology of Traumatic Brain Injury. We also reviewed the literature 
pertaining to major published guidelines in this area.  
3. Intracranial hypertension in TBI 
In comatose TBI patients with an abnormal CT scan, the incidence of ICH was 53–63% [75]. 
Patients with a normal CT scan at admission, on the other hand, had a relatively low 
incidence of ICH (13%). However, within the normal CT group, if patients demonstrated at 
least two of three adverse features (age over 40 years, unilateral or bilateral motor posturing, 
or systolic BP < 90 mm Hg); their risk of ICH was similar to that of patients with abnormal 
CT scans [75]. ICP is a strong predictor of outcome from severe TBI [5,6, 9,76-78]. Because of 
this, ethically a randomized trial of ICP monitoring with and without treatment is unlikely 
to be carried out. Similarly, a trial for treating or not treating systemic hypotension is not 
likely. Both hypotension and raised ICP are the leading causes of death in severe TBI. 
Furthermore, several studies have shown that patients who do not have ICH or who 
respond to ICP-lowering therapies have a lower mortality than those whose ICH does not 
respond to therapy [4-11, 79-82]. As a result, Guidelines for the Management of Severe TBI 
recommend that treatment should be initiated with ICP thresholds above 20 mm Hg (level 
II) as well as target a cerebral perfusion pressure (CPP) within the range of 50-70 (level III) 
[12]. Prevention and/or treatment of ICH is commonly accomplished by employing a  
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GOS = Glascow Outcome Score 
Table 1. Effects of Hypothermia on intracranial pressure and outcome in patients with severe 
Traumatic Brain Injury: Randomized Controlled Trials 
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progression of therapeutic approaches that are efficacious in controlling ICP and uniformly 
believed to be easily applied with minimal or rare negative side effects. These measures 
include elevation of the head of the bed , avoiding hypotension, hypoxia, and hypercapnea 
or prolonged hypocapnea, intravenous sedation and analgesia, episodic administration of 
hyperosmolar agents (mannitol, hypertonic saline), and CSF drainage [12]. Reviewing the 
evidence behind all these aforementioned therapies is beyond the scope of this review, but 
the evidence of efficacy for all of these treatments is variable at best. They are recommended 
not so much because there is clear-cut proof of morbidity or mortality benefit but because 
they are deemed treatments without significant downside. 
4. Therapeutic hypothermia for ICP control 
We identified a total of 18 studies involving hypothermia for control of ICP; 13 were 
randomized clinical trials and 5 were observational studies as shown in tables 1 and 2 
respectively [54, 58-74]. In all studies, the patient populations were comprised of TBI patients 
with GCS < 9 and an abnormal CT scan. ICP monitors were inserted in all patients to measure 
ICP. Individual study sizes ranged from 9 to 396 patients; a total of 1,773 patients were 
included in this review. Only three studies were multicenter [54,72,74]. The goals of therapy 
were stabilization or improvement of the patient’s neurological condition, and maintenance of 
an ICP of 20 mmHg or less (normal value in healthy subjects: ≤15 mmHg) and a cerebral 
perfusion pressure (CPP = MAP– ICP) of 60 mmHg or more or 70 mmHg or more. In patients 
with ICP higher than 20 mmHg, initial (standard) treatment included appropriate sedatives, 
narcotics, treatment with neuromuscular blockers (for ICP control and/or shivering) and 
administration of hyperosmolar therapy. Neurosurgical interventions were undertaken when 
necessary to evacuate subdural lesions or large intracerebral lesions [58, 61, 63, 64, 66-74]. In 
nine studies, there was no mention of the use barbiturates for ICP control [60, 62, 64, 68, 69, 71-
74]. In five of the studies, therapeutic hypothermia was applied after elevated ICP failed to 
respond to adequate sedation, hyperosmolar therapy and barbiturates [58, 63, 65-67]. In the 
other four studies [54,59, 61,70], patients were randomized to hypothermia or normothermia 
irrespective of ICP, with the goal of studying hypothermia’s role as a neuroprotectant 
(discussed below). ICP control was looked at as a secondary outcome in these four studies.  
Target temperature (320C – 34 0C) was achieved very quickly in most studies. Therapeutic 
hypothermia was maintained from 24 hrs up to 14 days depending on the study protocols. 
Some studies achieved re-warming passively over 10- 24 hrs [67,70, 71,73], but most studies 
achieved slow active rewarming over 12- 24 hrs as shown in tables 1 and 2. In one study, 
hypothermia maintenance for five days was associated with less rebound ICH than 
hypothermia for two days [72]. Therapeutic hypothermia was effective in controlling ICH in 
all studies as shown in tables 1 and 2 and figure 1. In the 13 RCT, ICP in the therapeutic 
hypothermia group was always lower than ICP in the normothermia group, and this 
difference always reached statistical significance as evidenced in table 1 and figure 1. In the 
5 observational studies, ICP during hypothermia was always lower then prior to inducing 
hypothermia; this difference also always reached statistical significance as shown in table 2. 
Therapeutic hypothermia also improved neurologic outcome and survival in eleven of the 
studies as can be seen in table 1.  
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GOS = Glascow Outcome Score 
Table 2. Effects of Hypothermia on intracranial pressure and outcome in patients with severe 
Traumatic Brain Injury: Nonrandomized Observational Trials 
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Reference: In Jiang 06, the comparison is between 2 days of hypothermia (red) and 5 days of hypothermia (blue) 
Figure 1. Effect of Hypothermia on Intracranial Pressure (ICP).  
5.Therapeutic hypothermia as a neuroprotectant 
The premise of the use of TH as a neuroprotectant in TBI is based on the fact that early 
administration of TH could halt the secondary injury processes discussed above, and thus 
possibly improve outcome. We identified a total of 9 studies where TH is used as a 
neuroprotectant in TBI, 5 of the studies designed to deliver TH as a neuroprotectant [54-
56,61,70], and 4 of the studies designed to deliver TH for neuroprotection and ICP control 
[48,64,72,73] (Table 3). In all studies, the patient populations were comprised of TBI patients 
with GCS < 9 and an abnormal CT scan. ICP monitors were inserted in all patients to 
measure ICP. Individual study sizes ranged from 26 to 392 patients. In the 4 studies 
designed to deliver hypothermia for ICP control and as a neuroprotectant, ICP in the TH 
group was always lower than ICP in the normothermia group, and this difference always 
reached statistical significance. Outcome was better in the hypothermia group in all of these 
4 studies.  
The 5 Trials designed with early administration of hypothermia for neuroprotection are 
described as such: 
 
Therapeutic Hypothermia in Traumatic Brain Injury 85 
Marion et al in 1997 enrolled 82 patients of ages 16–75 years where patients assigned to 
hypothermia were cooled to 330C a mean of 10 hours after injury, kept cool for 24 hours, and 
rewarmed over 24 hours [61]. At 1 year followup, 38 % of the patients in the hypothermia 
group and 62% of those in the normothermia group had poor outcomes (p = 0.05). The 
reported effect was exclusively in patients with admission GCS 5–7 [61]. Clifton in 2001 
enrolled 392 patients ages 16–65 years with target temperature of 330C reached by a little 
more than 8 hours after injury and maintained for 48 hours [54]. Rewarming was started at 
48 hours irrespective of ICP, at a rate of 0.50C every 2 hours. Outcome at 6 months was poor 
in 57% of patients in both groups. In subgroup analyses, adverse outcome was associated 
with hypothermia induction in patients older than 45 years of age, and better outcome was 
associated with maintenance of hypothermia in patients who were already hypothermic 
(<350C) on admission [54]. In this study, TH was started fairly late and cooling was slow 
(average time to target temperature >8 h), and there were problems with hypotension, 
hypovolemia, electrolytes, and hyperglycaemia. Hypotensive episodes lasting for more than 
2 h occurred three times more frequently in the hypothermia group than in the control 
group. Since even very brief episodes of hypotension or hypovolemia can adversely affect 
outcome in TBI, these problems might have greatly affected the results of this trial. In 2001, 
Shiozaki et al enrolled 91 patients who did not have elevated ICP in a study comparing the 
effect of 48 hours of hypothermia with normothermia [55]. There was no difference in 
outcome, with 53% of patients in the hypothermia group and 51% of patients in the 
normothermia group having poor outcomes. The incidences of pneumonia, meningitis, 
thrombocytopenia, leukocytopenia, hypernatremia, hypokalemia, and hyperamylasemia 
were higher in the hypothermia than in the normothermia group [55]. In 2005, Smrcka et al. 
reported a study of 72 patients in whom hypothermia maintained for 72 hours was 
compared to normothermia [70]. There was no difference in outcome between the two 
groups. However, patients treated with hypothermia with extracerebral hematomas but not 
diffuse brain injury had a significantly better Glasgow Outcome Score at 6 months than 
patients treated at normothermia [70]. In 2011, Clifton et al. started hypothermia in transit to 
or in the emergency department in a study enrolling 97 patients with TBI [56]. Hypothermia 
was maintained for 48 hours and patients rewarmed at 0.50C every 2 hours. A protocol of 
aggressive fluid expansion during rewarming and low dose morphine was used to prevent 
the hypotension that had complicated use of hypothermia in the group’s first study (above). 
Overall, there was no improvement in outcome at 6 months, but there was a difference in 
outcomes of patients with diffuse brain injury and those with evacuated hematomas ( p = 
0.001). Fewer patients with evacuated hematomas treated with hypothermia had poor 
outcomes (hypothermia - 33%, normothermia - 69%, p = 0.02), whereas more patients with 
diffuse brain injury treated with hypothermia had poor outcomes (hypothermia - 70%, 
normothermia - 50%, p = 0.09). Patients treated with hypothermia had a higher number of 
total episodes of elevated ICP, especially during rewarming [56]. Again, in this study, 
hypothermia was maintained for a fixed duration of only 48 hrs, and ICP elevations mainly 
occurred during and after rewarming. In addition, there were deviations from the protocol 
in this study, for example the decision to advance the interim analysis, and thus the 
enrollment of a smaller number of patients than planned. 
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Reference 
No. of 
patients
ICP 
control 
Neuro-
protection 
Length of 
cooling 
Outcome 
      
Abiki  
et al,2000 
26 yes yes 3 – 5 days positive 
Jiang  
et al,2000 
87 yes yes 3-14 days positive 
Jiang  
et al,2006 
215 yes yes 2 or 5 days positive 
Qui  
et al, 2007 
80 Yes Yes 4 days positive 
Marion  
et al,1997 
82  Yes 24 hours positive 
Clifton  
et al,2001 
392  Yes 48 hours No improvement 
Shiazaki  
et al,2001 
91  Yes 48 hours No improvement 
Smrcka  
et al,2005 
72  Yes 72 hours No improvement 
Clifton  
et al,2011 
97  Yes 48 hours No improvement 
Table 3. Studies where Therapeutic Hypothermia is used as a neuroprotectant. 
6. Side effects of therapeutic hypothermia in TBI 
Complications from hypothermia included electrolyte imbalances, increase in incidence of 
infections, thrombocytopenia, coagulopathy, arrhythmias (especially bradycardia), 
pancreatitis, and rebound ICH (during re-warming) as presented in tables 1 & 2. Particular 
consideration should be given to the rate of rewarming. In one extensive review [84], 
Povlishock et al showed that posttraumatic hypothermia followed by slow rewarming 
appeared to provide maximal protection in terms of traumatically induced axonal damage, 
microvascular damage and dysfunction, contusional expansion, intracranial hypertension, 
and neurocognitive recovery. In contrast, hypothermia followed by rapid rewarming not 
only reversed the protective effects associated with hypothermic intervention, but 
exacerbated the traumatically induced pathology and its neurologic consequences. 
Povlishock’s review concluded that the rate of posthypothermic rewarming is an important 
variable in assuring maximal efficacy following the use of hypothermic intervention. Two 
meta-analyses [12, 85] as well showed that duration >48 h and slow rewarming were 
associated with improved outcome. 
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7. Discussion 
Multiple trials, albeit observational or small single center randomized controlled studies, 
show that mild to moderate hypothermia consistently lowers high ICP in severe TBI 
patients as shown in figure 1. It is an accepted premise in the care of severe TBI patients that 
control of ICP improves survival and possibly neurologic outcome. It follows therefore that 
induced hypothermia in patients with poorly controlled ICP may be a reasonable 
therapeutic strategy when routine sedation, analgesia and neuromuscular paralysis fail. This 
benefit would be relevant regardless of any cellular or metabolic neuroprotective effect. 
Indeed, the additional potential neuroprotective benefits suggest that therapeutic 
hypothermia if without negative side effects should be implemented as a part of routine ICP 
control rather than as rescue therapy. It is puzzling why barbiturates with the well-known 
negative side effects are recommended while hypothermia with its known efficacy in 
controlling ICH is not. The reasons for this may be the relative inexperience with TH, 
complexity of TH implementation, concerns for adverse reactions, and the need for 
sophisticated technology [86,87]. In 2002, studies have indicated that TH with a reduction of 
body core temperature (T) to 33 °C over 12 to 24 hours has improved survival and 
neurologic outcome in cardiac arrest patients [88, 89]. A meta-analysis showed that 
therapeutic hypothermia for cardiac arrest patients was associated with a risk ratio of 1.68 
(95% CI, 1.29-2.07) favoring a good neurologic outcome when compared with normothermia 
[90]. The number needed to treat (NNT) to generate one favorable neurological recovery 
was 6. Subsequently, the International Liaison Committee on Resuscitation [91] and the 
American Heart Association [92] recommended the use of TH after sudden cardiac arrest. 
As a result, intensivists and neurointensivists have become much more familiar with the 
methodology (following cardiac arrest) so that the process is now familiar. And with 
appropriate hypothermia protocols, order sets, and education programs, mild hypothermia 
can be accomplished with very few side effects. It is important to note, however, that there 
are important differences between short duration hypothermia following cardiac arrest and 
long term hypothermia in TBI patients with ICH who frequently also have extracranial 
injuries and extra attention to the above mentioned side effects should be applied. 
Hypothermia should no longer be viewed as avant guard or dangerous, and we believe that 
it should take the place of barbiturates as the best modality for refractory ICH. Indeed, there 
is an argument, pending large scale studies, to consider it an extension of standard 
treatment. Pending large multicenter, randomized, controlled trials evaluating the effect of 
hypothermia on ICP control and outcome, the available data suggests that therapeutic 
hypothermia deserves at least a level II evidence recommendation for the treatment of 
refractory ICH.  
As for trials classified as designed for neuroprotection, although single-center studies 
were encouraging, multicenter trials with early administration of hypothermia for a 
defined period of time irrespective of ICP have almost uniformly been negative except 
maybe for patients undergoing craniotomy for hematoma evacuations. However, 
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hypothermia was maintained for a fixed duration of only 48 hrs, and ICP elevations 
mainly occurred during and after rewarming. These results suggest that a period of 48 
hours of hypothermia may be too short to have a beneficial effect on outcome. A 
standardized one size fit all may be inappropriate. The rate of rewarming plays an 
important role as well as pointed above. The rebound increase in ICP during and after 
rewarming in these studies and the encouraging outcomes from the randomized studies 
that induced hypothermia early and continued it throughout the period of ICP point to 
the realization that individualizing the duration of hypothermia to fit a patient’s ICP in 
future trials may be a better strategy than a predetermined period of hypothermia 
regardless of ICP. Another important finding is the differential effect of hypothermia in 
patients with surgical lesions versus those with diffuse injuries. This could be explained 
by the ability for volume expansion after surgery and thus less rebound ICP during and 
after rewarming. However, no final answer on this differential effect can be given at this 
stage, especially with the low number of patients studied so far. As a result, there is no 
reason to exclude patients with diffuse injury from future trials. 
8. Conclusion 
Preliminary evidence points to the effectiveness of mild to moderate therapeutic 
hypothermia in controlling ICH in severe TBI patients. The experience with induced 
hypothermia in the treatment of post cardiac arrest patients has demonstrated an acceptable 
safety profile when the modality is applied in specialized units by experienced personell 
according to a defined protocol. In addition, the above mentioned studies of therapeutic 
hypothermia in TBI patients show that the adverse effects of hypothermia are reasonable 
and managable when hypothermia is done in specialized and experienced ICUs. Pending 
results from large multicenter studies evaluating the effect of therapeutic hypothermia on 
ICH and outcome, therapeutic hypothermia should be included as a therapeutic option to 
control ICP in severe TBI patients. The most challenging issue appears to be rebound ICP 
during re-warming. We suggest that re-warming only be considered if the patient’s ICP is 
stable and <20mmHg for at least 48 hours, and, thereafter implemented at a rate not faster 
than 0.25°C per hour. As for future of hypothermia as a neuroprotectant in TBI patients 
irrespective of ICP, Individualizing the duration of hypothermia to fit a patient’s ICP in 
future trials is a better strategy than a predetermined period of hypothermia regardless of 
ICP. Design of these trials should also consider both the mechanism being tested and the 
differential effect between patients with evacuated hematomas and those with diffuse brain 
injury. 
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